Mvasi®

ACTIVE PRINCIPLE:
Bevacizumab

INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Ovarian, fallopian tube and peritoneal cancer
Cervical cancer

DATE:
27/09/2019

STATUS:
Authorized

MORE INFORMATION